Bank of New York Mellon Corp Sells 73,595 Shares of Biogen Inc. $BIIB

Key Points

• Bank of New York Mellon cut its Biogen stake by 8.3% in the fourth quarter, selling 73,595 shares and ending with 811,106 shares valued at about $142.7 million.
• Biogen reported better-than-expected quarterly results, with EPS of $3.57 versus $2.95 expected and revenue of $2.48 billion versus $2.29 billion expected. The company also reiterated FY2026 EPS guidance of 14.25 to 15.25.
• Recent pipeline updates were mostly positive, including FDA Breakthrough Therapy Designation for salanersen in SMA and progress on BIIB115, though the stock still faces some legal/investigation overhangs.

Bank of New York Mellon Corp decreased its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 8.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 811,106 shares of the biotechnology company's stock after selling 73,595 shares during the quarter. Bank of New York Mellon Corp owned about 0.55% of Biogen worth $142,747,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in BIIB. Norges Bank acquired a new position in Biogen in the 4th quarter valued at approximately $464,408,000. Orion Porfolio Solutions LLC raised its holdings in shares of Biogen by 6,828.4% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company's stock worth $64,965,000 after buying an additional 509,809 shares in the last quarter. Caisse de depot et placement du Quebec raised its holdings in shares of Biogen by 718.2% in the 3rd quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company's stock worth $79,741,000 after buying an additional 499,676 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Biogen by 30.7% in the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company's stock worth $248,809,000 after buying an additional 418,776 shares in the last quarter. Finally, Alyeska Investment Group L.P. raised its holdings in shares of Biogen by 66.1% in the 3rd quarter. Alyeska Investment Group L.P. now owns 845,277 shares of the biotechnology company's stock worth $118,406,000 after buying an additional 336,504 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Biogen Stock Down 0.6%

NASDAQ:BIIB opened at $195.34 on Friday. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $28.84 billion, a P/E ratio of 20.96, a P/E/G ratio of 1.72 and a beta of 0.20. The stock's fifty day simple moving average is $187.60 and its 200-day simple moving average is $183.33.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm's revenue was up 1.9% on a year-over-year basis. During the same period last year, the company earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts expect that Biogen Inc. will post 14.18 earnings per share for the current year.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s salanersen won FDA Breakthrough Therapy Designation for SMA, with early phase 1b data suggesting meaningful motor improvements and a once-yearly dosing profile that could make the therapy stand out commercially. BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
• Positive Sentiment: Biogen also highlighted progress on BIIB115 in post-gene therapy SMA, adding to investor optimism that the company has multiple shots on goal in a key neurodegeneration market. Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth
• Positive Sentiment: Biogen and UCB presented additional data on dapirolizumab pegol in lupus, showing reduced flare rates and lower steroid use, which supports the drug’s potential in a large autoimmune market. UCB and Biogen build steroid-sparing case for lupus drug
• Neutral Sentiment: Biogen is also facing legal overhang after law firms announced investor investigations and fraud-related claims, which could keep sentiment cautious even as pipeline news improves. BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
• Neutral Sentiment: A separate investor alert from Pomerantz also flagged a claims investigation into Biogen, adding another potential risk factor, though it does not yet indicate any formal enforcement action. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Canaccord Genuity Group increased their target price on Biogen from $230.00 to $245.00 and gave the stock a "buy" rating in a report on Wednesday, April 1st. Oppenheimer raised their price target on Biogen from $275.00 to $300.00 and gave the company an "outperform" rating in a report on Thursday, May 14th. Mizuho raised their price target on Biogen from $207.00 to $236.00 and gave the company an "outperform" rating in a report on Tuesday, February 10th. Wells Fargo & Company raised their price target on Biogen from $190.00 to $200.00 and gave the company an "equal weight" rating in a report on Sunday, February 8th. Finally, Wedbush raised their price target on Biogen from $191.00 to $196.00 and gave the company a "neutral" rating in a report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $215.81.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.